Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...

The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...

The latest research on chronic myeloid leukemia (CML) presented at the 2024 American Society of Hematology 2024 Annual Meeting and Exposition is reported by Dr Jorge Cortes from Georgia Cancer Center ...

After being diagnosed with chronic myeloid leukemia, graphic designer Aaron von Freter was able to participate in a clinical trial that offered him hope of being cured. When Aaron von Freter learned ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

The MarketWatch News Department was not involved in the creation of this content. -- Scemblix(R) is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III ...

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...

Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...